Binimetinib/Encorafenib Combo Approaches European Approval for BRAF+ Melanoma

July 27, 2018 – The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended approval of the combination of the BRAF inhibitor encorafenib and the MEK inhibitor binimetinib for the treatment of adult patients with BRAF V600–mutant unresectable or metastatic melanoma, according to Array BioPharma, the company developing the regimen. The CHMP recommendation is based on the phase III COLUMBUS trial, in which at a … (leggi tutto)